A theoretical analysis of long-term bisphosphonate effects on trabecular
bone volume and microdamage
Jeffry S. Nyman, a,* Oscar C. Yeh, b Scott J. Hazelwood, b and R. Bruce Martin b
a

Biomedical Engineering Graduate Group, College of Engineering, University of California at Davis, Davis, CA 95616, USA
b
Department of Orthopaedic Surgery, School of Medicine, University of California at Davis, Davis, CA 95616, USA

Abstract
Bisphosphonates increase bone mass and reduce fracture risk, but their anti-resorptive action may lead to increases in fatigue
microdamage. To investigate how bisphosphonate effects influence changes in bone volume and microdamage in the long term, a strainadaptive model of bone remodeling and microdamage balance was developed for a continuum-level volume of postmenopausal trabecular
bone by invoking Frost’s mechanostat hypothesis. Both disuse and fatigue microdamage were assumed to stimulate the activation frequency
of basic multicellular units (BMUs) such that bone remodeling served to remove excess bone mass and microdamage. Bisphosphonate effects
were simulated as follows: low, intermediate, high, or complete suppression of BMU activation frequency either without a change in
resorption by the BMU or with an independent decrease in resorption while the bone formation process was unaffected (i.e., formation
initially exceeded resorption). Of the bisphosphonate effects, a reduction in resorption relative to formation dictated the long-term gain in
bone volume while the potency of activation frequency suppression controlled the rate of gain. A plateau in the bone mass gain that typically
occurs in clinical studies of bisphosphonate treatment was predicted by the model because the resultant reduction in strain forced bone
formation by the BMU to decrease over time until it matched the reduction in BMU resorption. A greater suppression of activation frequency
proportionally increased microdamage, but the accumulation was limited over the long term as long as remodeling was incompletely
suppressed. The results of the model suggest creating bisphosphonates that provide minimal suppression of remodeling and a large decrease
in BMU resorption because this would minimize damage accumulation and increase bone mass, respectively.

Introduction
With the ability to suppress osteoclastic function, bis
phosphonates are being developed as drugs for treating
diseases involving elevated bone remodeling, such as
Paget’s disease, bone metastases, and postmenopausal oste
oporosis. They have a high affinity for bone mineral [1],
selectively bind to hydroxyapatite exposed by resorbing
activity [2], and assert their anti-resorptive effect upon
coming in contact with osteoclasts [3]. A wide range in
the degree of osteoclastic suppression exists for various
bisphosphonate drugs [4]. Those with high potency
(>100 that of etidronate, a first generation drug) can

suppress resorption at a relatively low dose, thus avoiding
another biological effect of bisphosphonates, the physico
chemical impairment of mineralization [4].
The suppression of bone resorption by bisphosphonates
involves cellular mechanisms that may be direct, such as
disruption of osteoclastic differentiation, or indirect, such as
increasing inhibitory signals from cells of the osteoblastic
lineage [5]. In either case, bisphosphonates inhibit activation
of new basic multicellular units (BMUs). Other possible
mechanisms include shortening osteoclasts’ life span by
inducing apoptosis [6] or decreasing their resorbing effi
ciency by disrupting their cytoskeleton [7]. These actions
reduce the size of resorption site created by the BMU.
Currently, the dominant mechanisms are not clear, but
presumably depend on the chemical structure of the partic
ular bisphosphonate.
At tissue level, mechanisms for the increase in bone mass
following treatment with bisphosphonates include reduced

remodeling space (the temporary porosity created by active
BMUs) and a positive bone balance (less bone is removed
than replenished at individual remodeling sites) [7]. In
addition, reduced bone turnover allows more time for
mineralization of existing bone, which increases bone den
sity but not volume [7].
Although bisphosphonates reduce fracture risk for post
menopausal women [8], the associated reduction in bone
remodeling has impaired the removal of microdamage and
reduced the toughness of bone in a canine model [9,10].
Human vertebral cancellous bone with more in vivo microdamage has been observed to be weaker than similar bone
with less damage [11]. Coupled with increased mineraliza
tion, which makes bone more brittle and less resistant to
crack propagation, microdamage accumulation following
bisphosphonate treatment of high potency may, in the long
term, increase fracture risk despite an increase in bone
mass.
Several studies have developed computational models
that simulate bisphosphonate effects on bone mass or
volume when varying such remodeling parameters as
BMU activation frequency, resorption and formation peri
ods, bone balance, and mineralization [12 – 15]. These
models successfully approximated clinically measured
changes in bone mineral density (BMD) associated with
initiation of treatment. However, they did not simulate
functional stimuli of remodeling that may be important in
subsequent years. Three that have been identified are
mechanical loading, estrogen, and microdamage.
Remodeling activation in a disuse state, when mechan
ical strains are reduced below physiologic levels, has been
demonstrated for both cortical and trabecular bone in animal
models as well as human subjects [16]. It has been hypoth
esized that a ‘‘mechanostat’’, comprised of the syncytium of
osteocytes and bone lining cells, senses bone strains and
activates remodeling when these strains fall below a thresh
old or set point [17]. This hypothesis is adopted here as the
first remodeling stimulus.
Estrogen deficiency also promotes remodeling, and there
is evidence that this response is closely related to the

mechanostat [18]. Estrogen deficiency is associated with
osteocyte apoptosis [19,20], and strain affects estrogen
response elements in cells of the osteoblast lineage [21].
Thus in theory, estrogen withdrawal shifts the mechanostat
set point so that normal mechanical loading elicits a disuse
response. Estrogen deficiency is therefore the second
remodeling stimulus in the model presented here.
Finally, as noted above, remodeling is activated by, and
apparently serves to remove, bone microdamage via a
pathway that again involves osteocyte apoptosis [22,23].
Thus, fatigue microdamage is the third remodeling stimulus
incorporated in the model.
Using a computational model for trabecular bone remod
eling that incorporates these remodeling stimuli, we inves
tigated the following question: under what conditions of
activation frequency suppression and BMU level resorption
reduction will an anti-resorptive drug increase bone mass
without causing an accumulation of microdamage? Specif
ically, the relative contributions of these bisphosphonate
actions to long-term changes in bone volume and microdamage were assessed.

Materials and methods
Mechanical loading
A model by Hazelwood et al. [24] was modified to
simulate adaptive remodeling in a 1 cm3 representative
volume (RV) of trabecular bone (Fig. 1A) under uniaxial
cyclic loading with a maximum stress (r) of 1 MPa (Table
1). The continuum-level elastic modulus (E) or apparent
stiffness of this RV was assumed to be proportional to its
bone volume fraction (BV/TV) as follows:
E ¼ E0  ðBV=TVÞb

ð1Þ

Here, E0 is a tissue modulus calculated from an empirically
derived relationship between bone stiffness and apparent

Fig. 1. A representative volume of bone (A) was subjected to cyclic loading, and bone remodeling was tracked within a representative cross-section (B). At the
BMU level, the ratio of resorption to formation was equal to 1 under normal conditions, greater than 1 with normal bisphosphonate treatment, and less than 1
when disuse conditions exist (C).

Table 1
Nomenclature and description of the model state variables and parameters
with values obtained from simulations of premenopausal trabecular and
postmenopausal trabecular bone remodeling as described in the text
State variable
or parametera
E, MPa
BV/TV

Description

Elastic modulus
Bone volume
fraction
p
Porosity
Microstrain
e (106)
Loading potential
U (1010)
Cr.S.Dn
Total crack length
per section area
(mm mm2)
Ac.f
BMUs appearing
(# day1 mm2) in representative
section per day
N.F.BMU
Number of
refilling sites
(# mm2)
N.Rs.BMU
Number of
resorbing sites
(# mm2)
BS/TA
Bone surface area
per section area
Approximated
Ac.f (year1)
mineralizing
surface fraction
per formation
period
Disuse threshold
U0
Load cycles
RL
per day
Damage removal
Fs
specificity factor
BMU refilling
FAr (mm2)
areac
BMU resorption
Rs.Ar (mm2)
aread
FP (day)
BMU refilling
period
Rs.P (day)
BMU resorbing
period
Rv.P (day)
BMU reversal
period

Premenopausal 15-year
trabecular
postmenopausal
bone
1708
0.196

0.780
502
1.902
0.0671

0.804
585
3.521
0.0879

0.0111

0.0156

Fatigue microdamage and bone remodeling were char
acterized in terms of histomorphometric variables observ
able in a representative section (RS) through the RV (Fig.
1B). The model tracked fatigue microdamage within the RS
based on assumptions about damage generation by mechan
ical loading and its removal by remodeling. Following
Martin [28], the damage removal rate was modeled as

0.708

1.000

dðDR Þ=dt ¼ Cr:S:Dn  Ac:f  Rs:Ar  Fs

0.277

0.391

2.37

2.16

0.254

0.395b

1.875
3000

3.469
3000

5

5

0.014176

0.014176

0.014176

0.014176

64

64

25

25

5

5

ð4Þ

where Cr.S.Dn (mm mm2) is the microcrack surface
density (total microcrack length in the RS), Ac.f is the
number of BMUs appearing in the RS per day, Rs.Ar is the
area of each completed resorption bay, and Fs (assumed to
be 5) is a specificity factor accounting for targeted remodel
ing (i.e., spatial association between resorption spaces and
microcracks is greater than what can be explained by
random remodeling [29]). The damage formation rate
dDF/dt was assumed to be proportional to the loading
potential,
dðDF Þ=dt ¼ kD  U

ð5Þ

The coefficient kD = 2.77  105 mm mm2 was chosen to
make damage formation equal damage removal under the
initial remodeling conditions [24]. The use of U to drive
damage formation was based on the observations from ex
vivo bone fatigue tests: damage accumulates during cyclic
loading and the number of cycles to failure is inversely
proportional to the strain range raised to a power [30].

density (q), E = 5546 q1.33 [25], assuming q is equal to (BV/
TV)*2.1 g cm3. Hence, E0 is 14,900 MPa and b is 1.33.
Peak strain was then given by Hooke’s Law as
ð2Þ

When modeling bone’s responses to mechanical loading,
it is common practice to define a loading potential or
stimulus that characterizes the mechanical environment for
the given boundary conditions [24,26,27]. Following this
practice, the loading potential (U) was defined here as
U ¼ RL  eq

Microdamage

1993
0.220

The 15-year postmenopausal values were assumed in the model at the
initiation of bisphosphonate treatment.
a
Initial values were obtained from the model of Hazelwood et al. [24],
except initial Ac.f, which was equal to 0.01 BMUs/day/mm2.
b
Typical of postmenopausal bone [38].
c
Decreases when bone is in disuse.
d
Decreases when bisphosphonate is active.

e ¼ r=e

where RL = 3000 is the loading frequency in cycles per day,
q = 4 adjusts the relative contribution of peak strain and
loading frequency to the loading potential [24], and e is the
peak strain as calculated in Eq. (2).

ð3Þ

Bone volume fraction
Changes in bone volume fraction depended on the
difference between the amounts of bone being added by
osteoblasts and removed by osteoclasts. In the context of the
RS, one may write for the rate of change of BV/TV,
dðBV=TVÞ=dt ¼

FAr
Rs:Ar
 N:F:BMU 
 N:Rs:BMU
FP
Rs:P
ð6Þ

Here, N.F.BMU and N.Rs.BMU are the numbers of forming
and resorbing sites per unit area, respectively. FAr and
Rs.Ar are completed formation and resorption areas (mm2)
within the RS, and FP and Rs.P are formation and resorption
periods (days), respectively, for the average BMU (Table 1).
As BMUs were activated within the RS, the model tracked
their individual progress through the resorption, reversal,

and refilling phases of remodeling, thereby calculating the
resulting changes in BV/TV.
BMU activation
Activation frequency of BMUs was assumed to depend
on the amount of microdamage present, the existence and
severity of a disuse state, and the available surface area for
the initiation of new BMUs. The latter was obtained by
converting BV/TV to porosity ( p = 1  BV/TV) and using
an empirical relationship for bone surface per total sectional
area (BS/TA) as a function of porosity [31],
BS
¼ 32:1p  93:9p2 þ 134p3  101p4 þ 28:8p5
TA

ð7Þ

Ac.f (as # mm2 day1) was calculated using hypothetical
dose-response curves for BMU activation in response to
disuse and microdamage (Fig. 2) and scaled by a normalized
BS/TA (varied between 0 and 1) [24].
Bone mass maintains equilibrium for certain combina
tions of cyclic loading frequency and strain range. Based on
the analysis of this relationship by Beaupré et al. [26], an
equilibrium loading stimulus or threshold U0 (i.e., the
mechanostat set point) was set to 1.875  1010 cycles
day1. (For example, 3000 cycles of loading per day at a
range of 500 peak microstrain maintains bone mass.)
Activation frequency and bone loss were assumed to be
inversely proportional to U, when U < U0. Bone loss at the
BMU level occurred by reducing formation as follows
�
�
1
U
ð8Þ
when U < U0
FAr ¼ FAr norm 1 þ
U0
2
where FArnorm (mm2) is the normal formation area. When
U z U0, FAr = FArnorm.
Microdamage also initiates the activation of BMUs
[32]. Therefore, an additional component of activation
frequency was modeled as occurring in proportion to

Cr.S.Dn (Fig. 2B). Lacking data for this response function,
it was again constructed by fitting a sigmoidal curve
through observed ranges of values for Ac.f and Cr.S.Dn
[24,28].
Activation frequency in trabecular bone is usually cal
culated as
Ac:f ¼

MS=BS
FP

ð9Þ

where MS/BS is the fraction of the bone surface that is
mineralizing. To present the changes in Ac.f following
simulated bisphosphonate treatment that reflects this form
of calculation, BMU resorption cavities were assumed to be
semicircular in geometry with a cement line radius similar to
a cortical bone osteon, taken to be 0.095 mm. This radius
then became the erosion cavity depth (E.De). The average
mineralizing surface of a BMU was assumed to occur at the
halfway point in refilling and to equal the perimeter of a
semicircle (i.e., mineralizing surface equaled E.De  p / 2).
With this in mind, Eq. (9) was calculated as
Ac:f ¼ 365 

p E:De  N:F:BMU
2

FP  BS=TA

ð10Þ

with the units being mineralizing surface fraction per
formation period measured in years. An E.De of 0.095
mm may understandably seem rather deep for a trabecular
BMU, but the somewhat exaggerated radius may compen
sate for a tendency of trabecular BMUs to be broad as well
as shallow relative to osteonal BMUs [33].
Simulation of estrogen-deficient remodeling
Menopause was simulated by invoking the hypothesis
that estrogen deficiency increases the strain threshold of a
mediator of remodeling in marrow that causes BMUs to
remove more bone than is replenished [34]. In other words,
estrogen deficiency invokes the equivalent of disuse remod-

Fig. 2. Activation frequency of BMUs increased as the mechanical stimulus decreased when bone was in disuse (A). The mechanostat set point (U0) was
linearly increased by 85% over 3 years to simulate the effect of estrogen withdrawal that produces bone loss observed during menopause. Ac.f also increased as
a function of the level of microdamage (B).

eling [35]. To model this, an associated change in the
mechanostat set point that would simulate the 11% average
loss in BMD as observed in the lumbar spines of healthy
women 5 years after menopause [36] was sought. With the
model initially running in an equilibrium state (Table 1),
linearly increasing U0 by 85% over a 3-year period (Fig. 2A)
achieved this goal. Using this model, 15 years of untreated
estrogen-deficient remodeling were simulated. Finally, from
the remodeling conditions of this 15-year postmenopausal
model (Table 1), the effects of bisphosphonate treatment
were studied.
Simulation of bisphosphonate effects
Bisphosphonate treatment was assumed to diminish both
activation frequency [37 –41] and the size of each completed
resorption bay [9,10]. Assuming that different bisphospho
nates inhibit osteoclast activation to varying degrees, a
potency variable 0 V P V 1 was introduced to quantify
the effectiveness of suppressing activation frequency. Mul
tiplying activation frequency by (1  P) simulated the
ability of bisphosphonate to suppress remodeling activation.
Independent of this suppression, the effect of treatment on
the completed size of BMU resorption cavities was simu
lated by reducing Rs.Ar by 1/6 or 3/13, which provided
erosion depths within 1 standard deviation of the means as
measured in transiliac bone biopsies from postmenopausal
women given 5 and 10 mg of alendronate daily, respectively,
for 1 year [38]. These reductions achieved an initial bone
balance ratio of 1.2 and 1.3, respectively, because before
treatment equilibrium remodeling conditions existed (i.e.,
FAr equaled Rs.Ar and a disuse state did not exist).
The pharmacokinetic properties of bisphosphonates in
clude the following: (1) potency of suppression depends on
chemical structure and dosage; (2) the drug binds preferen
tially to regions of high remodeling activity, mostly sites of
bone resorption; (3) uptake of the drug can saturate; and (4)
the action of the drug occurs on the osteoclast [3,42].
Therefore, potency was modeled as a function of the
numbers of resorbing sites,
P ¼ Pmax ð1  ess N:Rs:BMU Þ

ð11Þ

where Pmax and ss are suppression coefficients. Conceptu
ally, both coefficients reflect the dosage and structure of the
bisphosphonate (i.e., high dose alendronate would have
higher ss and higher Pmax than low dose etidronate). Values
of Pmax and ss were chosen to provide a range of potency
(high, intermediate, low) and cause reductions in activation
frequency that were within 1 standard deviation of the means
as measured after 1 year for daily alendronate (at 5 or 10 mg)
and daily pamidronate (at 150 mg) treatment [37,39].
Bisphosphonate effects were simulated in a sensitivity
analysis on the suppression coefficients and reduction in
resorption area (Table 2) to study the relative contributions
of activation frequency suppression and a reduction in BMU

Table 2
Sensitivity analysis of bisphosphonate effects simulated by the model

A

B

C

Level of
suppression

Pmax

ss

Initial
potency

Initial bone
balance

High
Intermediate
Intermediate
Low
High
Intermediate
Intermediate
Low
High
Intermediate
Intermediate
Low

1.0
0.7
1.0
0.7
1.0
0.7
1.0
0.7
1.0
0.7
1.0
0.7

20
20
5
5
20
20
5
5
20
20
5
5

0.9996
0.6997
0.8583
0.6008
0.9996
0.6997
0.8583
0.6008
0.9996
0.6997
0.8583
0.6008

1.0
1.0
1.0
1.0
1.2
1.2
1.2
1.2
1.3
1.3
1.3
1.3

level resorption to changes in bone volume and microdamage. All simulations were programmed in FORTRAN
77 and run on a UNIX workstation (Ultra 10, Sun Microsystems, Santa Clara, CA). The time step was 1 day.
Because bisphosphonates are quickly taken up by the
skeleton, their effects were invoked on day 0 [42].

Results
As the potency of activation frequency suppression
increased, the model predicted increasing gains in bone
volume over the first 3 months of treatment (Fig. 3A).
These represented varying degrees of remodeling space
recovery (i.e., porosity due to active BMUs fills in with
mineralized bone). If treatment completely stopped remod
eling, the ensuing full recovery of the model’s remodeling
space increased BV/TV by 5.27%. If the resorption area was
unaffected and remodeling was not completely inhibited, the
recovered BV/TV decayed over a period of several years
(lower curves in Fig. 3A).
When bisphosphonate treatment reduced resorption area
as well as activation frequency, the model predicted not only
the short-term increase in BV/TV (due to the loss in
remodeling space) but also a substantial additional increase
(Figs. 3B and 3C) that plateaus over the long term due to an
improved bone balance ratio (FAr/Rs.Ar > 1) in each BMU.
When the initial bone balance ratio was 1.2 (resorption area
reduced by 1/6) or 1.3 (resorption area reduced by 3/13), the
model simulated the rate of increase in bone volume that
paralleled the increases in BMD observed by Tonino et al.
[43] using alendronate doses of 5 or 10 mg day1, respec
tively. Greater potency of activation frequency suppression
slowed the rate of this secondary gain in bone volume
because there were fewer BMUs (Fig. 5) working to add
bone.
The model predicted that microdamage would increase
linearly without limit if the activation frequency was com
pletely suppressed, as would be expected, but limited
microdamage accumulation was predicted if remodeling

resorption area, which improves bone balance, microdam
age decreased further, irrespective of potency (Fig. 4C).
This happened because, as the resulting positive bone
balance increased bone volume (Fig. 3C), strain and U

Fig. 3. BV/TV as percent increase from baseline for different potencies of
suppressing activation frequency was predicted to increase then decrease
when there was no reduction in resorption area (A), but to rapidly increase
over the first 3 months and then gradually approach an asymptote when the
resorption area is reduced by 1/6 (B). The gain in bone volume was greater
for a 3/13 reduction in resorption area (C). Corresponding clinical data
obtained from Tonino et al. [43] are shown for 5 mg (B, circles) and 10 mg
(C, triangles) dosages.

was incompletely suppressed (Fig. 4A). Coupling incom
plete activation frequency suppression with a reduction in
resorption area, microdamage initially accumulated but then
decreased slightly in the long term, except in the case of
high suppression (Fig. 4B). With further diminishment of

Fig. 4. Percent increase in microdamage (calculated as crack length per unit
area) is unlimited when bone resorption is completely suppressed or limited
when bone resorption is incompletely suppressed (A). The level of
microdamage accumulation is greater for higher potency of activation
frequency suppression and resorption area is reduced by 1/6 (B), but in the
long term microdamage may fall below pretreatment level with intermediate
or low potency suppression and 3/13 reduction in resorption area (C).

declined (Eqs. 1 – 3), decreasing damage formation (Eq. (5)).
In addition, the diminished U increased remodeling activity
over time (Fig. 5C) via the disuse response, which in turn

increased damage removal (Eq. 4). Thus, even though a
smaller resorption space is likely to remove less damage,
this effect can be overridden by the reduction in strain and
damage formation associated with increased bone mass.
Lowering the maximum theoretical potency Pmax to 0.7,
combined with improved bone balance, decreased microdamage accumulation to the point that microdamage even
tually fell below its initial value (Fig. 4C), and activation
frequency climbed above its initial value (Fig. 5C). How
ever, a potent bisphosphonate (e.g., Pmax = 1.0 and ss = 20)
did not lower damage accumulation (Figs. 4 and 5B)
because a greater suppression of remodeling activity results
in fewer numbers of resorbing BMUs compared to a weak
bisphosphonate (e.g., Pmax = 0.7 and ss = 5).

Discussion

Fig. 5. Activation frequency (expressed as mineralizing surface per bone
surface per year) has a greater decrease for a greater suppression of bone
resorption (A). Activation frequency has a greater rebound for lower
potency (B). In the case of a 3/13 reduction in resorption area, activation
frequency may exceed pretreatment values when the theoretical maximum
potency is equal to 0.7 (C).

To gain a better understanding of the long-term contri
butions of bisphosphonate effects on bone mass and microdamage accumulation, a computer model simulated the
effects of suppressing BMU activation frequency and re
ducing BMU resorption on bone remodeling under the
influence of three fundamental stimuli: mechanical disuse,
estrogen deficiency, and fatigue microdamage. Based on the
model’s predictions, a drug that (1) does not completely
suppress remodeling activation and (2) creates a positive
bone balance at the BMU level by reducing resorption size
may permanently increase bone volume (and hence mass
and strength) with limited microdamage accumulation. The
model also predicts that the effects of bisphosphonate
treatment on bone mass and microdamage may require a
decade or more to reach a new equilibrium.
By combining the remodeling stimuli of mechanical
disuse, estrogen deficiency, and fatigue damage, the bone
remodeling simulations of the present study demonstrated
the potential contributions of microdamage accumulation
and disuse as important mechanisms affecting the long-term
effects of bisphosphonate treatment on bone volume. Spe
cifically, the immediate bisphosphonate effects of reduced
remodeling space and suppressed remodeling activation
frequency resulted in lowered strain (due to an increase in
BV/TV) and increased microdamage (due to a reduction in
damage removal), respectively. These consequences, in turn,
stimulated activation frequency (Fig. 5) and through the
disuse pathway decreased bone formation (i.e., reduced the
BMU level bone balance ratio). Thus, when simulating less
than complete suppression of bone resorption with a de
crease in activation frequency but no change in BMU level
erosion (Rs.Ar), reduced strains and increased microdamage
caused a transient increase in BV/TV with little or no longterm bone gain. Furthermore, the simulations emphasized
the importance of reduced resorption area as an important
contributor to long-term gains in bone volume and the
importance of the disuse response in causing the plateau
of bone gain.

In contrast, previous models [12 – 15], which did not
include the mechanical remodeling stimuli of disuse and
damage, predicted only permanent bone gain. In addition,
unlimited linear increases in bone mass (i.e., no plateau)
occurred over the long term when there was a fixed
reduction in activation frequency with positive bone turn
over within the BMU [12,13]. Authors of earlier computa
tional studies attributed the asymptotic limit to increases in
bone mass following inhibition of bone resorption to the
closure and mineralization of a portion of the remodeling
space [14,44]. Activation frequency, not BMU level resorp
tion, was interpreted to have the greatest influence on
changes in bone mass [14]. Notably, in the bisphosphonate
simulation by Hernandez et al. [13] that incorporated a
secondary mineralization period with a neutral bone balance
ratio, a plateau of bone gain occurred that matched a 7-year
clinical observation. This study suggested that mineraliza
tion as a function of remodeling activity may be the primary
contributor to bone mass gains following bisphosphonate
treatment. However, the present study suggests that clini
cally observed gains in bone mass (Figs. 3B and 3C) may
also be achieved through a positive shift in the BMU level
bone balance, and this bone gain would reach a plateau
when equilibrium is achieved among remodeling activity,
mechanical disuse, and microdamage.
Consistent with previous simulations [13,44], the mag
nitude of the initial bone gain was dependent on the potency
of activation frequency suppression and changes in the
BMU level bone balance. Further, the magnitude of the
secondary or long-term bone gain was also strongly depen
dent on the bone balance [13] with the initial increase in
bone volume depending on the remodeling conditions
before treatment [12].
There is evidence from animal studies that bisphospho
nate treatment increases bone volume as indicated by the
model, but the time course for these increases is not known
because of the invasive nature of such measurements. In
addition, while posttreatment increases in BV/TV, as mea
sured histomorphometrically at one time point, were not
statistically significant in human transiliac biopsy studies,
this lack of significance may be due to an insufficient
sample size [45]. Nonetheless, with quantitative computed
tomography of ex vivo specimens, bisphosphonates were
found to significantly increase BV/TV. For example,
increases in trabecular thickness and BV/TV as well as
decreases in trabecular separation have been observed for
the vertebrae of normal, skeletally mature dogs treated with
bisphosphonates [9,46]. With regards to estrogen-deficient
bone, ovariectomized (Ovx) rats treated with either tiludro
nate or ibandronate had significantly greater BV/TV than
the Ovx controls [47,48]. In addition, Ovx minipigs treated
with risedronate were found to have significantly greater
BV/TV than the Ovx controls [49].
The present model predicted a limited increase in microdamage that was proportionate to activation frequency
suppression. While a search of the literature does not reveal

any measurements of microdamage following bisphospho
nate treatment in humans, four times more microdamage (as
Cr.S.Dn) was observed in the second lumbar vertebra from
normal beagles treated daily for 1 year with 1.0 mg kg1 of
alendronate (causing a 95% suppression of activation fre
quency) than in the control group [9]. Furthermore, three
times more microdamage was observed in the second
thoracic vertebra from beagles treated daily for 3 years with
0.3 mg kg1 day1 of incadronate (67% suppression of
activation frequency) than in the control group [10]. It is
unclear whether the increases in microdamage in the years
immediately following the initiation of treatment, as either
predicted by the model or experimentally observed, would
increase the propensity of bone to fracture. Comparing the
vertebral fracture occurrence after 7 years of a clinical trial
with alendronate (6.2% at 5 mg and 6.6% at 10 mg) to the
occurrence after the trial’s first 3 years (2.9% at 5 mg and
2.8% at 10 mg) suggests that the fracture risk in bisphosph
onate-treated, postmenopausal women increases over time
[43,50]. This trend may be due to increases in fatigue
microdamage and brittleness caused by the pharmacologic
decrease in remodeling. Such increases have been associat
ed with a decrease in cortical bone toughness [51,52]. In
addition, the toughness of vertebral bone following
bisphosphonate treatment was 20 – 40% less than the tough
ness of control bone in dog studies [9,10]. Age-related
changes in bone (e.g., weakening of the collagen network)
could also explain the increase in fracture with increase in
treatment time. Nonetheless, the model suggests that greater
potency in suppressing BMU activation frequency could
prolong elevated microdamage.
As previously stated, the present model simulates clini
cally observed increases in BMD (Figs. 3B and 3C), though
it does not account for the contribution of secondary
mineralization. With a reduction in the bone turnover rate
following bisphosphonate treatment, BMU bone packets
have more time to mineralize before they are replaced
[13]. The expectation that this would contribute to increased
BMD is supported by quantitative microradiography and
backscattered electron scanning of transiliac biopsies from
postmenopausal women, which showed that 3 years of
alendronate treatment significantly increased and homoge
nized mineral content in the iliac crest [53,54]. Bisphosph
onate-induced changes in BMU level bone balance and
secondary mineralization are likely additive in their effects
on BMD. A lack of secondary mineralization in the model
complicates the direct comparison of its predicted changes
in BV/TV to clinical changes in BMD. However, its
predictions about the long-term effects of bisphosphonate
treatment on BV/TV should parallel the expectations for
increased BMD.
As with any theoretical study, the present results must be
interpreted in light of the limiting assumptions. First, it was
assumed that bisphosphonates would not affect the targeting
of BMUs to remove damage in the model (i.e., the speci
ficity factor Fs in Eq. (4) was kept constant). This is

inconsistent with the observation by Li et al. [55] that the
association of resorption spaces with microdamage was
reduced by alendronate treatment. Thus, the model may
have overpredicted damage removal. Second, a bone mod
eling response was not included. One mechanism to prevent
fracture when significant fatigue microdamage is present in
bone is periosteal bone formation, which lowers the stress.
Mashiba et al. [56] observed that the ribs of alendronate
treated dogs had increased the cortical area as well as
microdamage, and the present model did not replicate the
protection afforded by such modeling. If such a response
was included by reducing the stress on the representative
volume (r < 1 MPa), damage formation would have been
less. Third, decreases or increases in loading activity that
may occur with aging or exercising were not studied in this
initial analysis, although the model has the capacity to
incorporate such effects. Clearly, such changes could affect
the bone volume and microdamage responses associated
with bisphosphonate treatment. Fourth, BMU level bone
formation was assumed to equal bone resorption at the start
of treatment. While the representative bone volume had
experienced a history of a negative imbalance (when estro
gen withdrawal was simulated to create the initial postmen
opausal remodeling conditions), the model was allowed to
run for 15 years without treatment and a new quasi-equi
librium state was reached. Clearly, assuming an initial bone
balance of 1 (to reduce complexity) may not accurately
represent clinical postmenopausal, osteoporotic bone. It is
perhaps more likely that the initial bone balance would be
less than 1 (i.e., formation is less than resorption). Because
the control of bone balance in the model is multifaceted,
bisphosphonate effects on bone initially in a state of
negative turnover at the BMU level would depend on what
caused this effect (e.g., decrease in loading, increase in the
mechanostat set point, or some other factor negatively
impacting osteoblast function). Lastly, irreversible bone loss
due to trabecular perforations, an important mechanism in
the development of osteoporosis [15], was not modeled.
Including such an effect would increase strain and damage
formation.
Despite the assumptions and simplifications, the present
study illustrates the potential significance of designing antiresorptive drugs that allow BMU level resorption and BMU
activation suppression to be independently controlled. On
one hand, it is important to maintain bone turnover so as to
prevent damage accumulation. On the other hand, it is
important to control the size of the resorption space so as
to achieve better bone balance and reduce the risk of
trabecular perforation. The ideal anti-resorptive agent would
produce a positive bone balance at the BMU level by
decreasing erosion without substantially decreasing BMU
activation frequency. While reducing erosion depth would
diminish the effectiveness of damage removal by remodel
ing to some extent, the present model suggests that the
achievement of a positive bone balance would ultimately
control damage formation by reducing bone strain.
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